Alexipharmic Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Alexipharmic Drugs Market is Segmented by Application (Alcoholic Overdose, Opioid Overdose, Benzodiazepine Overdose, Cyanide Poisoning, and Others), End-user, and Geography

Alexipharmic Drugs Market Size

Compare market size and growth of Alexipharmic Drugs Market with other markets in Healthcare Industry

Alexipharmic Drugs Market Analysis

The Alexipharmic Drugs Market is expected to register a CAGR of 4.9% during the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall alexipharmic drugs market owing to the rise in the number of cancers, plastic surgery, diabetic ulcer amputation cases, and others that necessitate the prescription of these drugs and driving the market growth in the region. As per the United States Department of Health and Human Services (HHS) report, about 70,237 drug overdose deaths were recorded in 2017 with a significant increase in deaths by 9.6% to that of 2016 in the United States. Also, the report emphasizes that opioids resulted in 47,600 deaths representing 67.8% of all drug overdose deaths in 2017. Thus, higher incidences of drug overdose deaths in the region demand immediate and effective alexipharmic drugs propelling the growth of the market in the region.

Alexipharmic Drugs Industry Overview

The alexipharmic drugs market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some prominent players are developing new products with lesser side effects and launching across the world. In October 2018, The National Agency for the Safety of Medicines and Healthcare Products (ANSM) granted marketing authorization to Ethypharm for its drug Baclocur in France for the first time in the world. Baclocur is a range of baclofen tablets in doses of 10, 20 and 40 mg prescribed for alcohol-dependent adult patients with high-risk alcohol consumption. Launch of such medication-assisted treatment (MAT) products will positively impact the market growth over the course of the forecast period. Some of the companies which are currently dominating the market are Bausch Health Companies Inc, Fresenius SE & Co. KGaA (Fresenius Kabi), Ethypharm S. A., Mylan N.V., and Emergent BioSolutions

Alexipharmic Drugs Market Leaders

  1. Fresenius SE & Co. KGaA (Fresenius Kabi)

  2. Mylan N.V.

  3. Ethypharm S.A.

  4. Emergent BioSolutions Inc

  5. Bausch Health Companies Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF

Alexipharmic Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Dependence on Psychoactive Substances and Narcotic Drugs
    • 4.2.2 Favorable Initiatives by Regulatory Agencies to Develop Medication-assisted Treatment (MAT) Products
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Medication and Treatment Procedures
    • 4.3.2 Increased Adoption of Alternative Treatments and Emerging Abuse-Deterrent Formulations (ADFs)
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Application
    • 5.1.1 Alcholic Overdose
    • 5.1.2 Opioid Overdose
    • 5.1.3 Benzodiazepine Overdose
    • 5.1.4 Cyanide Poisoning
    • 5.1.5 Others
  • 5.2 End-user
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Retail Pharmacies
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United states
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bausch Health Companies Inc
    • 6.1.2 Ethypharm S. A.
    • 6.1.3 Fresenius SE & Co. KGaA (Fresenius Kabi)
    • 6.1.4 Alkermes, Inc.
    • 6.1.5 Mylan N.V.
    • 6.1.6 B. Braun Melsungen AG
    • 6.1.7 Emergent BioSolutions
    • 6.1.8 Hikma Pharmaceuticals
    • 6.1.9 SGPharma Pvt. Ltd.
    • 6.1.10 Merck & Co., Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Alexipharmic Drugs Industry Segmentation

Alexipharmic drugs are medications that act as an antidote used to reverse or reduce the effects of a drug overdose, and drug poisoning. These are employed in an emergency shot to save lives quickly and can be used to defend against various types of microbial infections. As per the scope of the report, various alexipharmic drugs used in drug overdose and poisoning cases were described in detail.

Application Alcholic Overdose
Opioid Overdose
Benzodiazepine Overdose
Cyanide Poisoning
Others
End-user Hospital Pharmacies
Retail Pharmacies
Others
Geography North America United states
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Application
Alcholic Overdose
Opioid Overdose
Benzodiazepine Overdose
Cyanide Poisoning
Others
End-user
Hospital Pharmacies
Retail Pharmacies
Others
Geography
North America United states
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Alexipharmic Drugs Market Research FAQs

What is the current Alexipharmic Drugs Market size?

The Alexipharmic Drugs Market is projected to register a CAGR of 4.9% during the forecast period (2025-2030)

Who are the key players in Alexipharmic Drugs Market?

Fresenius SE & Co. KGaA (Fresenius Kabi), Mylan N.V., Ethypharm S.A., Emergent BioSolutions Inc and Bausch Health Companies Inc. are the major companies operating in the Alexipharmic Drugs Market.

Which is the fastest growing region in Alexipharmic Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Alexipharmic Drugs Market?

In 2025, the North America accounts for the largest market share in Alexipharmic Drugs Market.

What years does this Alexipharmic Drugs Market cover?

The report covers the Alexipharmic Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Alexipharmic Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Our Best Selling Reports

Alexipharmic Drugs Industry Report

Statistics for the 2025 Alexipharmic Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Alexipharmic Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Alexipharmic Drugs Report Snapshots

Access Report